Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School. Boston, MA 02115, USA.
Channing Department of Network Medicine, Brigham and Women's Hospital, Harvard Medical School. Boston, MA 02115, USA.
Hypertension. 2015 Jan;65(1):211-217. doi: 10.1161/HYPERTENSIONAHA.114.04233. Epub 2014 Nov 3.
Striatin is a novel protein that interacts with steroid receptors and modifies rapid, nongenomic activity in vitro. We tested the hypothesis that striatin would in turn affect mineralocorticoid receptor function and consequently sodium, water, and blood pressure homeostasis in an animal model. We evaluated salt sensitivity of blood pressure in novel striatin heterozygote knockout mice. Compared with wild type, striatin heterozygote exhibited a significant increase in blood pressure when sodium intake was increased from restricted (0.03%) to liberal (1.6%) sodium. Furthermore, renal expression of mineralocorticoid receptor and its genomic downstream targets serum/glucocorticoid-regulated kinase 1, and epithelial sodium channel was increased in striatin heterozygote versus wild-type mice on liberal sodium intake while the pAkt/Akt ratio, readout of mineralocorticoid receptor's rapid, nongenomic pathway, was reduced. To determine the potential clinical relevance of these findings, we tested the association between single nucleotide polymorphic variants of striatin gene and salt sensitivity of blood pressure in 366 white hypertensive subjects. HapMap-derived tagging single nucleotide polymorphisms identified an association of rs2540923 with salt sensitivity of blood pressure (odds ratio, 6.25; 95% confidence interval, 1.7-20; P=0.01). These data provide the first in vivo evidence in humans and rodents that associates striatin with markers of mineralocorticoid receptor activity. The data also support the hypothesis that the rapid, nongenomic mineralocorticoid receptor pathway (mediated via striatin) has a role in modulating the interaction between salt intake and blood pressure.
Striatin 是一种新型蛋白,可与甾体激素受体相互作用,并在体外改变快速的非基因组活性。我们检验了这样一种假设,即 striatin 反过来会影响盐皮质激素受体的功能,并由此影响动物模型中钠、水和血压的稳态。我们评估了新型 striatin 杂合子敲除小鼠的血压对盐的敏感性。与野生型相比,当钠摄入量从限制(0.03%)增加到自由(1.6%)时,striatin 杂合子的血压显著升高。此外,在高盐饮食时,striatin 杂合子小鼠的肾盐皮质激素受体及其基因组下游靶标血清/糖皮质激素调节激酶 1 和上皮钠通道的表达增加,而 pAkt/Akt 比值(盐皮质激素受体快速非基因组途径的读出)则降低。为了确定这些发现的潜在临床相关性,我们在 366 名白人高血压患者中检测了 striatin 基因单核苷酸多态性变异与血压对盐的敏感性之间的关系。HapMap 衍生的标记单核苷酸多态性鉴定出 rs2540923 与血压对盐的敏感性相关(比值比,6.25;95%置信区间,1.7-20;P=0.01)。这些数据提供了在人类和啮齿动物中 striatin 与盐皮质激素受体活性标志物相关的首个体内证据。这些数据还支持了快速的非基因组盐皮质激素受体途径(通过 striatin 介导)在调节盐摄入和血压之间相互作用的假说。